JNJ

Business profile & competitive position

Johnson & Johnson is classified under the Healthcare sector, specifically the Drug Manufacturers - General industry. In practical terms, it operates as a holding company whose subsidiaries employ roughly 138,200 full-time-equivalent staff worldwide and are engaged in researching, developing, manufacturing, and selling healthcare products. The business is organized into two reportable segments: Innovative Medicine, which focuses on prescription therapeutics in areas such as Oncology, Immunology, Neuroscience, Pulmonary Hypertension, Infectious Diseases, and Cardiovascular and Metabolism; and MedTech, which supplies products used in cardiovascular, orthopaedics, surgery, and vision procedures. Its distribution network reaches retailers, wholesalers, distributors, hospitals, eye-care professionals, and healthcare providers in virtually all countries of the world.

The numbers behind the business suggest a wide, durable competitive footprint. A net margin of 21.5% and an ROE of 25.7% are well above what commodity-like healthcare businesses typically produce, pointing to pricing power, scale economies, and a portfolio of therapies that face limited interchangeability. In 2025, DARZALEX / DARZALEX FASPRO accounted for approximately 15.0% of total revenues, STELARA for about 6.5%, and TREMFYA for about 5.5%. Concentration in a handful of blockbusters creates both cash-flow strength and patent-life risk, but the aggregate margin profile indicates that Johnson & Johnson’s moat is real and measurable rather than merely narrative.

Financial posture

With a market capitalization of $655.7 billion, Johnson & Johnson is one of the largest listed healthcare franchises. It currently trades at a P/E ratio of 31.5. Against a market that often assigns mid-to-high-teens multiples to diversified industrials, that P/E implies investors are paying a premium for the company’s combination of profitability, defensive characteristics, and global diversification. The supporting fundamentals are strong: net margin 21.5% and ROE 25.7%, both signs that management is converting revenue into shareholder returns efficiently.

The stock’s current snapshot shows a price of $272.09, an RSI of 58.4, and a 50-day EMA of $264.44. The price sits above its 50-day moving average, while the RSI is neutral and not in overbought territory. The beta of 0.23 reinforces the stock’s defensive profile: historically, the shares have moved far less than the broad market, which is consistent with a business that sells essential healthcare products regardless of the economic cycle.

Strategic priorities & outlook

The company’s most recent 10-K filing outlines a clear operational agenda. The headline priority is completing the planned separation of the Orthopaedics business, announced in October 2025, with a targeted completion within 18 to 24 months of that announcement. The move is intended to sharpen the remaining company around Innovative Medicine and MedTech, while allowing Orthopaedics to operate with its own capital-allocation and growth strategy.

Beyond portfolio restructuring, management emphasizes human capital and culture. Its human capital strategy is built on three stated pillars: attracting and recruiting top talent, developing and retaining top talent, and empowering and inspiring talent. The company also says it is cultivating a Credo-based culture of innovation, health, well-being, safety, inclusion, and belonging, and is fostering a learning environment through tools such as J&J Learn and the annual Global Learning Day. These initiatives are framed as support for long-term strategy rather than short-term restructuring.

Operationally, the filing flags a couple of important revenue dynamics. While DARZALEX / DARZALEX FASPRO supplied roughly 15.0% of 2025 revenue, the company expects continued global launches of biosimilar versions of STELARA to keep pressuring that product’s sales. It also notes that worldwide sales do not reflect significant seasonality, but that fourth-quarter spending is typically heavier, driven mainly by advertising and R&D decisions.

Macro & geopolitical exposure

As a global drug manufacturer, Johnson & Johnson is exposed to the full regulatory and reimbursement environment for pharmaceuticals and medical devices. That includes oversight by bodies such as the U.S. Food and Drug Administration and comparable agencies abroad, plus ongoing legislative and political pressure around drug pricing. Changes to Medicare/Medicaid reimbursement or international reference-pricing regimes can directly affect realized revenue for high-margin medicines.

Patent expirations and biosimilar competition are persistent industry-level risks, and the 10-K itself cites STELARA biosimilars as a headwind. Foreign exchange is another macro channel: because products are sold in virtually all countries of the world, a stronger U.S. dollar can compress reported sales and earnings when overseas results are translated back. Supply-chain and manufacturing quality also matter, given the global physical footprint and regulatory scrutiny of medical-device and pharmaceutical plants. Trade policy, tariffs on active pharmaceutical ingredients or finished devices, and geopolitical friction in key markets can therefore feed through to margins without necessarily changing end demand.

Recent developments

Recent headlines show the stock being discussed primarily through an income and relative-quality lens. On September 26, 2026, 247wallst.com included Johnson & Johnson in “Want Bulletproof Dividend Income? These 3 Stocks Have Raised Payouts Through 8 Major Downturns,” while Seeking Alpha featured it in “Best Dividend Kings: September 2026” the same day. Both pieces point to the company’s long record of dividend growth and its status as a defensive holding.

On September 25, 2026, Fool.com published “AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?”—a comparison that, by its nature, frames J&J as a core healthcare peer rather than a speculative name. Also on September 25, Benzinga reported “Johnson & Johnson Clinical Trials Show Progress Across Key Therapies,” suggesting the pipeline remains active and is generating incremental news flow ahead of the next earnings report.

Earnings behavior & post-earnings drift

Johnson & Johnson’s earnings track record has been remarkably consistent. Over the last eight reported quarters, the company is listed at 7/8 (100%) on the beat rate, with an average earnings surprise of 3.4%. The average five-day post-earnings price move across those quarters is +0.67%, classified as an “up” drift.

The most recent four quarters illustrate both the consistency and the short-term noise around the headline. On July 15, 2026, J&J reported EPS of $2.90 against an estimate of $2.84, a 2.1% surprise; the stock rose 1.19% the next day and 3.49% over the following five sessions. On April 14, 2026, EPS of $2.70 beat the $2.68 estimate by 0.7%, yet the shares fell 0.60% the next day and 5.81% over the next five. On January 21, 2026, the report was exactly in line at $2.46, producing a 0.22% next-day gain and a 4.45% five-day rally. Finally, on October 14, 2025, EPS of $2.80 topped the $2.76 estimate by 1.4%, with the stock up 0.17% the next day and 0.54% over the following five sessions.

The next scheduled report is October 13, 2026, before the market open, with a current consensus EPS estimate of $2.85. The post-earnings drift history suggests that even when headline beats are modest, the stock has frequently drifted higher over the following week, although the April 2026 example shows that a beat is not a guarantee of immediate price appreciation. For a deeper dive into how sell-side models and institutional positioning view the upcoming quarter, readers should consult the full institutional verdict page for JNJ.